# Human metapneumovirus infection is associated with a substantial morbidity and mortality burden in adult inpatients

Quentin Philippot, Blandine Rammaert, Gaëlle Dauriat, Cédric Daubin, Frédéric Schlemmer, Adrien Costantini, Yacine Tandjaoui-Lambiotte, Mathilde Neuville, Emmanuelle Desrochettes, Alexis Ferré, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Quentin Philippot, Blandine Rammaert, Gaëlle Dauriat, Cédric Daubin, Frédéric Schlemmer, et al. Human metapneumovirus infection is associated with a substantial morbidity and mortality burden in adult inpatients. Heliyon, 2024, 10 (13), pp.e33231. 10.1016/j.heliyon.2024.e33231. hal-04789274

HAL Id: hal-04789274

https://hal.science/hal-04789274v1

Submitted on 18 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Research article

Human metapneumovirus infection is associated with a
substantial morbidity and mortality burden in adult inpatients

Quentin Philippot<sup>a, *</sup>, Blandine Rammaert<sup>b</sup>, Gaëlle Dauriat<sup>c</sup>, Cédric Daubin<sup>d</sup>, Frédéric Schlemmer<sup>e,f</sup>, Adrien Costantini<sup>g</sup>, Yacine Tandjaoui-Lambiotte<sup>h</sup>, Mathilde Neuville<sup>i</sup>, Emmanuelle Desrochettes<sup>j</sup>, Alexis Ferré<sup>k</sup>, Laetitia Bodet Contentin<sup>l</sup>, François-Xavier Lescure<sup>m</sup>, Bruno Megarbane<sup>n</sup>, Antoine Belle<sup>o</sup>, Jean Dellamonica<sup>p</sup>, Sylvain Jaffuel<sup>q</sup>, Jean-Luc Meynard<sup>r</sup>, Jonathan Messika<sup>s</sup>, Nicolas Lau<sup>t</sup>, Nicolas Terzi<sup>u</sup>, Isabelle Runge<sup>v</sup>, Olivier Sanchez<sup>w</sup>, Benjamin Zuber<sup>x</sup>, Emmanuel Guerot<sup>y</sup>, Anahita Rouze<sup>z</sup>, Patricia Pavese<sup>aa</sup>, François Bénézit<sup>ab</sup>, Jean-Pierre Quenot<sup>ac</sup>, Xavier Souloy<sup>ad</sup>, Anne Lyse Fanton<sup>ae</sup>, David Boutoille<sup>af</sup>, Vincent Bunel<sup>c</sup>, Astrid Vabret<sup>ag</sup>, Jacques Gaillat<sup>ah</sup>, Anne Bergeron<sup>ai</sup>, Nathanaël Lapidus<sup>aj</sup>, Muriel Fartoukh<sup>ak</sup>, Guillaume Voiriot<sup>al, **</sup>

<footnote>ª Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France</footnote>

<footnote>ᵇ Maladies infectieuses et tropicales, CHU de Poitiers, France</footnote>

<footnote>ᶜ Service de Pneumologie B, Hôpital Bichat, Paris, France</footnote>

<footnote>d CHU de Caen Normandie, médecine intensive réanimation, 14000, CAEN, France</footnote>

<footnote>e Université Paris Est Créteil, Faculté de Santé, INSERM, IMRB, Créteil, France</footnote>

<footnote>f AP-HP, Hôpitaux Universitaires Henri Mondor, Unité de Pneumologie, Service de Médecine Intensive et Réanimation, Créteil, France</footnote>

<footnote>g Service de Pneumologie, APHP, Hôpital Saint Louis, France</footnote>

<footnote>ᵇ Service de médecine intensive réanimation, AP-HP, Hôpital Avicenne, France</footnote>

<footnote n="1">¹ Service de médecine intensive réanimation, AP-HP, Hôpital Bichat Claude-Bernard, France</footnote>

<footnote>j Service de médecine intensive réanimation, AP-HP, Hôpital Saint Antoine, France</footnote>

<footnote>ᵇ Service de réanimation médico-chirurgicale, centre hospitalier de Versailles, France</footnote>

<footnote n="1">¹ Médecine Intensive Réanimation, INSERM CIC 1415, CRICS-TriGGERSep Network, CHRU de Tours and methodS in Patient-Centered Outcomes and Health ResEarch (SPHERE), INSERM UMR 1246, Université de Tours, Tours, France</footnote>

<footnote>m Maladies infectieuses et tropicales, APHP, Hôpital Bichat Claude Bernard, France</footnote>

<footnote>n Service de médecine intensive réanimation, AP-HP, Hôpital Lariboisière, France</footnote>

<footnote>° Service de pneumologie, centre hospitalier intercommunal Compiegne Moyon, France</footnote>

<footnote>P Service de médecine intensive réanimation, UR2CA - Université Cote d'Azur, CHU de Nice, France</footnote>

<footnote>q Service de maladies infectieuses et tropicales, CHRU de Brest, France</footnote>

<footnote>Maladies infectieuses et tropicales, AP-HP, Hôpital Saint Antoine, France</footnote>

<footnote>Réanimation médico-chirurgicale, AP-HP, Hôpital Louis Mourier, France</footnote>

<footnote>Réanimation, surveillance continue, Site de Longiumeau Groupe Hospitalier Nord-Essone, France</footnote>

<footnote>ᵇ Médecine Intensive Réanimation, CHU Grenoble Alpes, France</footnote>

<footnote>Médecine intensive réanimation, CHR d'Orléans, France</footnote>

<footnote>W Université Paris Cité, Service de pneumologie et soins Intensifs, HEGP, AP-HP Centre Université Paris Cité, France</footnote>

<footnote>x Réanimation polyvalente, hôpital Foch, France</footnote>

<footnote>Service de médecine intensive réanimation, AP-HP, HEGP, France</footnote>

<footnote>* Corresponding author. Service de Pneumologie A, Hôpital Bichat-Claude-Bernard, 46 rue Henri-Huchard, 75018, Paris, France.</footnote>

<footnote>** Corresponding author. Médecine Intensive Réanimation, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France.
E-mail addresses: philippot.quentin@gmail.com (Q. Philippot), guillaume.voiriot@aphp.fr (G. Voiriot).</footnote>
² Univ. Lille, Inserm U1285, CHU Lille, Service de Médecine Intensive – Réanimation, CNRS, UMR 8576, UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France

aa Service des maladies infectieuses, CHU Grenoble Alpes, France

ab Service de Maladies Infectieuses et Réanimation Médicale, CHU de Rennes, France

ac Service de médecine intensive réanimation, CHU de Dijon, France

ad Réanimation polyvalente, Centre hospitalier public du Cotentin, France

ae Service de pneumologie et soins intensifs respiratoires, CHU Dijon Bourgogne, France

af Service de maladies infectieuses et tropicales, CHU de Nantes, France

ag FèNoMIH, CHU de Caen et de Rouen, GRAM EA2656, laboratoire de virologie, Normandie université, CHU de Caen, France

ah Service des maladies infectieuses, Hôpital d'Annecy, France

ai Service de pneumologie, Hôpitaux universitaires de Genève, Genève, Switzerland

al Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, Public Health Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France

ak Sorbonne Université, Groupe de Recherche Clinique CARMAS Université Paris Est Créteil, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France

al Sorbonne Université, Centre de Recherche Saint-Antoine UMRS_938 INSERM, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France

ARTICLE INFO

Keywords:

Human metapneumovirus

Pneumonia

Viral pneumonia

Respiratory viruses

ABSTRACT

**Background:** Human metapneumovirus (hMPV) is one of the leading respiratory viruses. This prospective observational study aimed to describe the clinical features and the outcomes of hMPV-associated lower respiratory tract infections in adult inpatients.

**Methods:** Consecutive adult patients admitted to one of the 31 participating centers with an acute lower respiratory tract infection and a respiratory multiplex PCR positive for hMPV were included. A primary composite end point of complicated course (hospital death and/or the need for invasive mechanical ventilation) was used.

**Results:** Between March 2018 and May 2019, 208 patients were included. The median age was 74 [62–84] years. Ninety-seven (47 %) patients were men, 187 (90 %) had at least one coexisting illness, and 67 (31 %) were immunocompromised. Median time between first symptoms and hospital admission was 3 [2–7] days. The two most frequent symptoms were dyspnea (86 %) and cough (85 %). The three most frequent clinical diagnoses were pneumonia (42 %), acute bronchitis (20 %) and acute exacerbation of chronic obstructive pulmonary disease (16 %). Among the 52 (25 %) patients who had a lung CT-scan, the most frequent abnormality was ground glass opacity (41 %). While over four-fifths of patients (81 %) received empirical antibiotic therapy, a bacterial coinfection was diagnosed in 61 (29 %) patients. Mixed flora (16 %) and enterobacteria (5 %) were the predominant documentations. The composite criterion of complicated course was assessable in 202 (97 %) patients, and present in 37 (18 %) of them. In the subpopulation of pneumonia patients (42 %), we observed a more complicated course in those with a bacterial coinfection (8/24, 33 %) as compared to those without (5/60, 8 %) (p = 0.02). Sixty (29 %) patients were admitted to the intensive care unit. Among them, 23 (38 %) patients required invasive mechanical ventilation. In multivariable analysis, tachycardia and alteration of consciousness were identified as risk factors for complicated course.

**Conclusion:** hMPV-associated lower respiratory tract infections in adult inpatients mostly involved elderly people with pre-existing conditions. Bacterial coinfection was present in nearly 30 % of the patients. The need for mechanical ventilation and/or the hospital death were observed in almost 20 % of the patients.

1. Introduction

Respiratory virus, including influenza and non-influenza viruses, are the most common pathogens documented in hospitalized patients suffering from community-acquired acute lower respiratory tract infection [1]. Among them, the human metapneumovirus (hMPV) is found in 3–8 % of cases [1–3]. hMPV belongs to the pneumoviridae and was first described in 2001 [4]. hMPV is genetically close to the respiratory syncytial virus (RSV) [4]. hMPV infections have a seasonal epidemic pattern, in late fall and early winter. The incubation period varies between four and six days [5]. Clinical symptoms are an influenza-like illness associated with signs of upper and/or acute lower respiratory tract infection. Life threatening hMPV infections have been described with admission to intensive care unit (ICU) of up to 30 % of hospitalized adults with hMPV infection [6]. Current therapeutic management is mainly symptomatic. However, several drug candidates have shown an activity on hMPV, and some additional targets have recently been identified [7–10]. As specific antiviral therapies will be available in clinical practice in the coming years, we pointed out an urgent need to better characterize hMPV infections, in order to better guide therapeutic management and use of forthcoming antiviral therapies. The present study aimed to describe the clinical, radiological and biological features, the course and outcomes of hMPV-associated lower respiratory tract infection in adult inpatients.
## 2. Methods

### 2.1. Study design and patient selection

We performed a prospective, observational, multicenter study in 24 secondary and seven tertiary care hospitals in France. From April 2018 to May 2019, all consecutive adult (≥18 years old) patients admitted to hospital with an acute lower respiratory tract infection and a respiratory multiplex Polymerase Chain Reaction (mPCR) test positive for hMPV within five days following hospital admission were included (for details regarding inclusion and exclusion criteria, see Electronic Supplementary Material, ESM). The mPCR used was the one available in the patient inclusion center, and may, therefore, differ between included patients (Table S1).

<table><caption>**Table 1**
Clinical characteristics of adult inpatients with hMPV-associated lower respiratory tract infection.</caption><thead><tr><th rowspan="2"></th><th colspan="3">Clinical diagnosis</th><th colspan="3">Complicated course</th></tr><tr><th>All patients<br/>N = 208</th><th>Non-pneumonia<br/>N = 115</th><th>Pneumonia<br/>N = 84</th><th>p-value</th><th>No<br/>N = 165</th><th>Yes<br/>N = 37</th><th>p-value</th></tr></thead><tbody><tr><td>Age (years)</td><td>74 [62-84]</td><td>73 [62-84]</td><td>75 [61-84]</td><td>0.78</td><td>73 [62-84]</td><td>79 [64-84]</td><td>0.30</td></tr><tr><td>&lt;30 years</td><td>3 (1.4)</td><td>1 (0.9)</td><td>2 (2.4)</td><td></td><td>2 (1.2)</td><td>1 (2.7)</td><td></td></tr><tr><td>30-60 years</td><td>41 (19.7)</td><td>21 (18.3)</td><td>18 (21.4)</td><td></td><td>35 (21.2)</td><td>5 (13.5)</td><td></td></tr><tr><td>&gt;60 years</td><td>164 (78.8)</td><td>93 (80.9)</td><td>64 (76.2)</td><td></td><td>128 (77.6)</td><td>31 (83.8)</td><td></td></tr><tr><td>Male sex</td><td>97 (46.6)</td><td>52 (45.2)</td><td>39 (46.4)</td><td>0.89</td><td>76 (46.1)</td><td>17 (45.9)</td><td>1</td></tr><tr><td>Former smoker</td><td>89 (47.1)</td><td>72 (47.7)</td><td>15 (45.5)</td><td>1</td><td>51 (48.1)</td><td>34 (43.6)</td><td>1</td></tr><tr><td>Current smoker</td><td>18 (9.5)</td><td>15 (9.9)</td><td>3 (9.1)</td><td>0.55</td><td>10 (9.4)</td><td>8 (10.3)</td><td>0.85</td></tr><tr><td>Time from symptom onset to hospital admission (days)</td><td>3 [2-7]</td><td>3 [2-7]</td><td>3 [1-6]</td><td>0.16</td><td>3 [2-7]</td><td>2 [1-4]</td><td>0.33</td></tr><tr><td>Body temperature (°C) at hospital admission</td><td></td><td></td><td></td><td>&lt;0.01</td><td></td><td></td><td>0.72</td></tr><tr><td>&lt;37.5</td><td>44 (22.8)</td><td>30 (28.6)</td><td>12 (14.5)</td><td></td><td>37 (24.2)</td><td>6 (17.6)</td><td></td></tr><tr><td>37.5-39.0</td><td>72 (37.3)</td><td>45 (42.9)</td><td>25 (30.1)</td><td></td><td>57 (37.3)</td><td>13 (38.2)</td><td></td></tr><tr><td>&gt;39</td><td>77 (39.9)</td><td>30 (28.6)</td><td>46 (55.4)</td><td></td><td>59 (38.6)</td><td>15 (44.1)</td><td></td></tr><tr><td>Symptoms and clinical signs at hospital admission<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nasal congestion</td><td>64 (34.4)</td><td>41 (41.0)</td><td>20 (24.7)</td><td>0.03</td><td>51 (34.7)</td><td>10 (30.3)</td><td>0.69</td></tr><tr><td>Headache</td><td>32 (17.3)</td><td>18 (18.2)</td><td>13 (16.0)</td><td>0.84</td><td>26 (17.8)</td><td>5 (15.2)</td><td>0.81</td></tr><tr><td>Cough</td><td>166 (84.7)</td><td>93 (85.3)</td><td>68 (82.9)</td><td>0.69</td><td>137 (87.8)</td><td>24 (70.6)</td><td>0.02</td></tr><tr><td>Sore throat</td><td>23 (12.6)</td><td>13 (13.4)</td><td>9 (11.1)</td><td>0.82</td><td>16 (11.1)</td><td>7 (21.2)</td><td>0.15</td></tr><tr><td>Sputum production</td><td>105 (53.3)</td><td>62 (56.4)</td><td>42 (51.2)</td><td>0.56</td><td>92 (58.6)</td><td>11 (32.4)</td><td>0.01</td></tr><tr><td>Asthenia</td><td>104 (54.7)</td><td>59 (56.7)</td><td>43 (52.4)</td><td>0.66</td><td>82 (54.7)</td><td>18 (52.9)</td><td>0.85</td></tr><tr><td>Dyspnoea</td><td>167 (85.6)</td><td>91 (84.3)</td><td>71 (86.6)</td><td>0.69</td><td>132 (85.7)</td><td>30 (85.7)</td><td>1</td></tr><tr><td>Nausea/vomiting</td><td>25 (13.2)</td><td>13 (12.6)</td><td>12 (14.6)</td><td>0.83</td><td>18 (12.0)</td><td>6 (17.6)</td><td>0.4</td></tr><tr><td>Diarrhea</td><td>21 (11.0)</td><td>9 (8.7)</td><td>11 (13.4)</td><td>0.35</td><td>17 (11.3)</td><td>4 (11.8)</td><td>1</td></tr><tr><td>Muscle ache</td><td>13 (7.1)</td><td>8 (8.2)</td><td>5 (6.2)</td><td>0.77</td><td>10 (7.0)</td><td>3 (9.1)</td><td>0.71</td></tr><tr><td>Wheezing</td><td>72 (36.9)</td><td>40 (36.7)</td><td>30 (37.0)</td><td>1</td><td>59 (37.8)</td><td>10 (30.3)</td><td>0.55</td></tr><tr><td>Crackles</td><td>106 (54.4)</td><td>55 (50.5)</td><td>47 (58.0)</td><td>0.31</td><td>79 (50.6)</td><td>23 (69.7)</td><td>0.06</td></tr><tr><td>Comorbidities<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>At least one</td><td>187 (89.9)</td><td>105 (91.3)</td><td>77 (91.7)</td><td>1</td><td>150 (90.9)</td><td>31 (83.8)</td><td>0.23</td></tr><tr><td>COPD</td><td>22 (10.9)</td><td>19 (17.0)</td><td>2 (2.4)</td><td>&lt;0.01</td><td>17 (10.6)</td><td>4 (11.4)</td><td>1</td></tr><tr><td>Non-COPD lung disease</td><td>66 (31.7)</td><td>43 (37.4)</td><td>21 (25.0)</td><td>0.07</td><td>56 (33.9)</td><td>8 (21.6)</td><td>0.17</td></tr><tr><td>Diabetes</td><td>22 (10.9)</td><td>10 (8.9)</td><td>12 (14.3)</td><td>0.26</td><td>15 (9.4)</td><td>6 (17.1)</td><td>0.23</td></tr><tr><td>Hypertension</td><td>105 (52.2)</td><td>57 (50.9)</td><td>44 (52.4)</td><td>0.89</td><td>79 (49.4)</td><td>21 (60.0)</td><td>0.27</td></tr><tr><td>Coronary heart disease</td><td>37 (18.5)</td><td>23 (20.7)</td><td>13 (15.5)</td><td>0.46</td><td>29 (18.2)</td><td>8 (22.9)</td><td>0.63</td></tr><tr><td>Cerebrovascular disease</td><td>20 (10.0)</td><td>10 (8.9)</td><td>9 (10.7)</td><td>0.81</td><td>17 (10.6)</td><td>3 (8.6)</td><td>1</td></tr><tr><td>Chronic renal disease</td><td>6 (3.0)</td><td>2 (1.8)</td><td>4 (4.8)</td><td>0.41</td><td>5 (3.1)</td><td>1 (2.9)</td><td>1</td></tr><tr><td>Chronic immunosuppression<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>At least one</td><td>64 (30.8)</td><td>30 (26.1)</td><td>32 (38)</td><td>0.09</td><td>49 (29.7)</td><td>11 (29.7)</td><td>1</td></tr><tr><td>HIV infection</td><td>3 (1.4)</td><td>2 (1.8)</td><td>1 (1.2)</td><td>1</td><td>2 (1.2)</td><td>1 (2.7)</td><td>0.45</td></tr><tr><td>Neutropenia (&lt;0.5 G/L)</td><td>1 (0.5)</td><td>1 (0.9)</td><td>0</td><td>1</td><td>0</td><td>1 (2.7)</td><td>0.18</td></tr><tr><td>Corticosteroid therapy</td><td>26 (12.5)</td><td>12</td><td>13 (15.4)</td><td>1</td><td>18 (10.9)</td><td>4 (11.4)</td><td>1</td></tr><tr><td>Immunosuppressive therapy</td><td>47 (22.6)</td><td>20 (17.4)</td><td>25 (29.8)</td><td>0.58</td><td>35 (21.2)</td><td>8 (21.6)</td><td>1</td></tr><tr><td>Solid organ transplantation</td><td>15 (7.2)</td><td>6 (5.2)</td><td>8 (9.5)</td><td>0.28</td><td>13 (7.9)</td><td>2 (5.4)</td><td>1</td></tr><tr><td>Bone marrow transplantation</td><td>10 (4.8)</td><td>4 (3.5)</td><td>6 (7.1)</td><td>0.33</td><td>9 (5.5)</td><td>1 (2.7)</td><td>1</td></tr><tr><td>Hemopathy/cancer</td><td>25 (12.0)</td><td>13 (11.3)</td><td>11 (13.1)</td><td>0.83</td><td>17 (10.3)</td><td>6 (16.2)</td><td>0.39</td></tr></tbody></table>

Data are presented as median [first through third quartiles] or number (%). Patients were classified according to the clinical diagnosis, which was available in 199 patients. Non-pneumonia diagnosis included bronchitis, acute exacerbation of COPD, exacerbation of interstitial lung disease, pulmonary edema, and other diagnosis. The composite criterion of “complicated course”, defined by death in hospital or at D60 or the need for invasive mechanical ventilation, was available for 202 patients.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; HIV, Human Immunodeficiency Virus.

<footnote>a multiple responses were possible.</footnote>
## 2.2. Data collection

For each recruited patient, pre-defined clinical, biological, microbiological and radiological data were collected by the investigator on an online electronic case report form (for details and definitions, see ESM and Table S2). Recruited patients were followed until hospital discharge (or until 60 days post-inclusion if the patient was still hospitalized).

## 2.3. Patient classification

Patients were classified according to the clinical diagnosis, determined by investigators for each patient using a six-class classification. The six mutually-exclusive classes of clinical diagnosis were: i) pneumonia, ii) bronchitis, iii) acute exacerbation of chronic obstructive pulmonary disease (COPD), iv) exacerbation of interstitial lung disease, v) pulmonary edema, and vi) other (for details regarding definitions used for patient classification, see ESM).

## 2.4. End points

The primary end point named "complicated course" was a composite of the death during hospital stay (censored at day-60) and/or the need for invasive mechanical ventilation.

## 2.5. Statistical analysis

Continuous data were expressed as median [first and third quartiles] and were compared using the non-parametric Mann-Whitney test. Categorical variables were expressed as numbers (percentages) and were evaluated using the Fischer exact test. P values less than 0.05 were considered significant. Comparisons focused on demographics, comorbidities, disease history, clinical, biological, microbiological and radiological findings, and hospital course, according to the primary composite end point. Characteristics of patients were also compared between those with a clinical diagnosis of pneumonia (pneumonia patients) versus those with another clinical diagnosis among the five other classes (non-pneumonia patients).

A multivariable logistic regression model was built to identify variables independently associated with the primary composite end point. All variables deemed clinically relevant were included without univariable screening. For this analysis, missing data were imputed using multiple imputation by chained equations: 30 datasets were imputed by predictive mean matching and logistic regression for continuous and binary variables, respectively, and estimates obtained from these datasets were pooled using Rubin's rule. All tests were two-tailed at the 0.05 significance threshold.

Analyses were performed using the R software version 4.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

<table><caption>**Table 2**
Radiological and laboratory findings in adult inpatients with hMPV-associated lower respiratory tract infection.</caption><thead><tr><th rowspan="2"></th><th colspan="3">Clinical diagnosis</th><th rowspan="2">p-value</th><th colspan="2">Complicated course</th><th rowspan="2">p-value</th></tr><tr><th>All patients<br/>N = 208</th><th>Non-pneumonia<br/>N = 115</th><th>Pneumonia<br/>N = 84</th><th>No<br/>N = 165</th><th>Yes<br/>N = 37</th></tr></thead><tbody><tr><td>Chest X-ray</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Unilateral opacity</td><td>105 (50.4)</td><td>44 (38.3)</td><td>59 (70.2)</td><td>&lt;0.01</td><td>80 (48.5)</td><td>22 (59.5)</td><td>0.28</td></tr><tr><td>Bilateral opacity</td><td>16 (7.7)</td><td>8 (7.0)</td><td>8 (9.5)</td><td>0.60</td><td>14 (8.5)</td><td>2 (5.4)</td><td>0.74</td></tr><tr><td>Pleural effusion</td><td>9 (5.1)</td><td>6 (6.0)</td><td>3 (4.2)</td><td>0.74</td><td>9 (6.3)</td><td>0 (0.0)</td><td>0.36</td></tr><tr><td>Chest CT</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Available<br/>Chest CT</td><td>52 (25.0)</td><td>21 (18.3)</td><td>27 (32.1)</td><td>0.03</td><td>35 (21.2)</td><td>12 (32.4)</td><td>0.20</td></tr><tr><td>Ground glass opacity</td><td>26 (41.3)</td><td>8 (29.6)</td><td>14 (43.8)</td><td>0.06</td><td>16 (35.6)</td><td>6 (46.2)</td><td>0.53</td></tr><tr><td>Alveolar condensation</td><td>23 (36.5)</td><td>7 (25.9)</td><td>17 (53.1)</td><td>0.29</td><td>15 (33.3)</td><td>8 (61.5)</td><td>0.11</td></tr><tr><td>Micronodule</td><td>26 (41.3)</td><td>14 (51.9)</td><td>11 (34.4)</td><td>0.20</td><td>18 (40.0)</td><td>7 (53.8)</td><td>0.53</td></tr><tr><td>Nodule</td><td>15 (23.8)</td><td>6 (22.2)</td><td>7 (21.9)</td><td>1</td><td>8 (17.8)</td><td>4 (30.8)</td><td>0.44</td></tr><tr><td>Pleural effusion</td><td>7 (11.1)</td><td>4 (14.8)</td><td>3 (9.4)</td><td>0.69</td><td>3 (6.7)</td><td>4 (30.8)</td><td>0.04</td></tr><tr><td>Laboratory findings</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Leukocyte count</td><td>8 [6-12]</td><td>8 [6-12]</td><td>8 [7-12]</td><td>0.93</td><td>8 [7-12]</td><td>9 [6-13]</td><td>0.90</td></tr><tr><td>Platelet count</td><td>203 [152-273]</td><td>210 [154-286]</td><td>196 [151-256]</td><td>0.24</td><td>208 [161-278]</td><td>186 [141-249]</td><td>0.25</td></tr><tr><td>CRP</td><td>46 [23-119]</td><td>41 [22-108]</td><td>66 [28-160]</td><td>0.07</td><td>43 [23-113]</td><td>98 [31-192]</td><td>0.05</td></tr><tr><td>Urea</td><td>8 [5-11]</td><td>7 [5-10]</td><td>9 [6-12]</td><td>0.05</td><td>7 [5-10]</td><td>9 [5-15]</td><td>0.13</td></tr><tr><td>Sodium</td><td>138 [135-140]</td><td>138 [136-140]</td><td>138 [134-139]</td><td>0.32</td><td>138 [136-140]</td><td>137 [133-139]</td><td>0.02</td></tr></tbody></table>

Data are presented as median [first through third quartiles] or number (%). Patients were classified according to the clinical diagnosis, which was available in 199 patients. Non-pneumonia diagnosis included bronchitis, acute exacerbation of COPD, exacerbation of interstitial lung disease, pulmonary edema, and other diagnosis. The composite criterion of "complicated course", defined by death in hospital or at D60 or the need for invasive mechanical ventilation, was available for 202 patients. Leukocyte and platelet counts are expressed in $10^9$/L, CRP in mg/L, urea and sodium in mmol/L.

Abbreviations: CT, Computed Tomography; CRP, C Reactive Protein.
## 2.6. Ethical considerations

This study was approved by the institutional review board of the French Society of Respiratory Diseases (Reference CEPRO 2017-037), and verbal informed consent was obtained from all the participants before enrollment, according to the French regulations.

# 3. Results

## 3.1. Initial presentation

During the 13-month study period, 208 patients were included in the 31 participating centers (Fig. S1). Their clinical characteristics are depicted in Table 1. Median age was 74 years [62–84] and 97 (47 %) were males. A large proportion (90 %) had at least one comorbidity, and near a third of patients (31 %) had at least one immunosuppressive condition. The median time from symptom onset to hospital admission was three [2–7] days. The two most frequent symptoms were dyspnea (86 %) and cough (85 %); the triad fever-cough-dyspnea was observed in 42 % of patients. Clinical diagnosis was available in only 199 patients. The three most frequent were pneumonia (40 %), acute bronchitis (20 %) and acute exacerbation of chronic obstructive pulmonary disease (16 %). Radiological and laboratory findings at hospital admission are depicted in Table 2. Only 16 (8 %) patients had bilateral opacities on chest X-ray. In the 52 patients who had a chest computerized tomography (chest-CT) in the 96 h following hospital admission, the two most frequent abnormalities were ground glass opacity (41 %) and centrilobular micronodules (41 %). Leukocytosis (>10 G/L) was present in 31 % of the patients, lymphopenia (<1.5 G/L) in 78 % and thrombocytopenia (<150 G/L) in 24 %. A viral coinfection was diagnosed in 26 (13 %) patients, with rhinovirus (5 %) and RSV (5 %) as predominant species (Table 3). A bacterial coinfection was diagnosed in 61 (29 %) patients, with mixed flora (16 %) and enterobacteria (5 %) as predominant documentations. Of note, the frequency of bacterial coinfection did not differ between pneumonia patients and non-pneumonia patients. Among patients without coinfection (“pure” hMPV infection), the clinical diagnosis was pneumonia in 42 % of cases.

## 3.2. Hospital course and outcomes

Hospital course and outcomes are depicted in Table 4. The primary composite end point was assessable in 202 patients. Among them, a complicated course was observed in 37 (18 %) patients, without difference between pneumonia patients and non-pneumonia patients (16 % vs. 19 %, p = 0.61) (Table S3). The multivariable analysis identified tachycardia and alteration of consciousness (Glasgow <15) as independently associated with a complicated course (Table S4). A majority of patients received empirical antibiotic therapy at hospital admission, but with a larger proportion in pneumonia patients (88 % vs. 76 %, p = 0.01). The median length of hospital stay was nine days [6–14]. Near a third of patients were admitted to the ICU, with a median length of ICU stay of six [3–9] days (Table S5). Among them, 38 % required invasive mechanical ventilation for a median duration of six [4–12] days. Hospital death

<caption>**Table 3**</caption>

Microbiological finding in adult inpatients with hMPV-associated lower respiratory tract infection.

<table><thead><tr><th rowspan="3"></th><th colspan="3">Final diagnosis</th><th rowspan="3">p-value</th><th colspan="2">Complicated course</th><th rowspan="3">p-value</th></tr><tr><th>All patients</th><th>Non-pneumonia</th><th>Pneumonia</th><th>No</th><th>Yes</th></tr><tr><th>N = 208</th><th>N = 115</th><th>N = 84</th><th>N = 165</th><th>N = 37</th></tr></thead><tbody><tr><td>Any virus</td><td>26 (12.5)</td><td>15 (13.0)</td><td>11 (13.1)</td><td>1</td><td>20 (12.1)</td><td>4 (10.8)</td><td>1</td></tr><tr><td>Rhinovirus</td><td>10 (4.8)</td><td>7 (6.1)</td><td>3 (3.6)</td><td>0.52</td><td>1 (0.6)</td><td>9 (24.3)</td><td>0.69</td></tr><tr><td>Respiratory syncital virus</td><td>10 (4.8)</td><td>4 (3.5)</td><td>0 (0)</td><td>0.33</td><td>2 (1.2)</td><td>7 (18.9)</td><td>0.67</td></tr><tr><td>Influenza virus</td><td>4 (1.9)</td><td>4 (3.5)</td><td>6 (7.1)</td><td>0.14</td><td>0 (0)</td><td>3 (8.1)</td><td>1</td></tr><tr><td>Bocavirus</td><td>3 (1.4)</td><td>3 (2.6)</td><td>2 (2.4)</td><td>0.57</td><td>1 (0.6)</td><td>2 (5.4)</td><td>0.33</td></tr><tr><td>Coronavirus</td><td>3 (1.4)</td><td>1 (0.9)</td><td>0 (0)</td><td>0.27</td><td>0 (0)</td><td>3 (8.1)</td><td>1</td></tr><tr><td>Adenovirus</td><td>2 (1)</td><td>1 (0.9)</td><td>1 (1.2)</td><td>1</td><td>0 (0)</td><td>2 (5.4)</td><td>1</td></tr><tr><td>Parainfluenza virus</td><td>1 (0.5)</td><td>1 (0.9)</td><td>0 (0)</td><td>1</td><td>0 (0)</td><td>1 (2.7)</td><td>1</td></tr><tr><td>Any bacteria</td><td>61 (29.3)</td><td>33 (28.7)</td><td>24 (28.6)</td><td>0.16</td><td>45 (27.3)</td><td>13 (35.1)</td><td>1</td></tr><tr><td>Mixed flora</td><td>33 (15.9)</td><td>19 (16.5)</td><td>10 (11.9)</td><td>0.42</td><td>24 (14.5)</td><td>7 (18.9)</td><td>0.46</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>8 (3.8)</td><td>5 (4.3)</td><td>3 (3.6)</td><td>1</td><td>5 (3)</td><td>3 (8.1)</td><td>0.16</td></tr><tr><td>Streptococcus pneumoniae</td><td>7 (3.4)</td><td>3 (2.6)</td><td>4 (4.8)</td><td>0.46</td><td>5 (3)</td><td>1 (2.7)</td><td>1</td></tr><tr><td>Other Streptococcus</td><td>2 (1)</td><td>0 (0)</td><td>1 (1.2)</td><td>0.42</td><td>1 (0.6)</td><td>1 (2.7)</td><td>0.33</td></tr><tr><td>Haemophilus influenzae</td><td>6 (2.9)</td><td>2 (1.7)</td><td>4 (4.8)</td><td>0.24</td><td>5 (3)</td><td>1 (2.7)</td><td>1</td></tr><tr><td>Enterobacteriaceae</td><td>11 (5.3)</td><td>5 (4.3)</td><td>6 (7.1)</td><td>0.53</td><td>10 (6.1)</td><td>1 (2.7)</td><td>0.69</td></tr><tr><td><i>Pseudomonas aeruginosa</i></td><td>4 (1.9)</td><td>3 (2.6)</td><td>1 (1.2)</td><td>0.64</td><td>3 (1.8)</td><td>1 (2.7)</td><td>0.56</td></tr><tr><td>Mycoplasma pneumoniae</td><td>6 (2.9)</td><td>1 (0.9)</td><td>5 (6)</td><td>0.08</td><td>5 (3)</td><td>1 (2.7)</td><td>1</td></tr><tr><td>Chlamydia pneumoniae</td><td>2 (1)</td><td>1 (0.9)</td><td>1 (1.2)</td><td>1</td><td>1 (0.6)</td><td>1 (2.7)</td><td>0.33</td></tr><tr><td><i>Legionella pneumophila</i></td><td>2 (1)</td><td>2 (1.7)</td><td>0 (0)</td><td>0.51</td><td>2 (1.2)</td><td>0 (0)</td><td>1</td></tr><tr><td>Bordetella pertussis</td><td>0 (0)</td><td>1 (0.9)</td><td>0 (0)</td><td>1</td><td>1 (0.6)</td><td>0 (0)</td><td>1</td></tr></tbody></table>

Data are presented as median [first through third quartiles] or number (%). Patients were classified according to the clinical diagnosis, which was available in 199 patients. Non-pneumonia diagnosis included bronchitis, acute exacerbation of COPD, exacerbation of interstitial lung disease, pulmonary edema, and other diagnosis. The composite criterion of “complicated course”, defined by death in hospital or at D60 or the need for invasive mechanical ventilation, was available for 202 patients.
<table><caption>**Table 4**
Hospital course and outcomes in adult inpatients with hMPV-associated lower respiratory tract infection.</caption><thead><tr><th rowspan="2"></th><th colspan="3">Final diagnosis</th><th rowspan="2">p-value</th><th colspan="2">Complicated course</th><th rowspan="2">p-value</th></tr><tr><th>All patients<br/>N = 208</th><th>Non-pneumonia<br/>N = 115</th><th>Pneumonia<br/>N = 84</th><th>No<br/>N = 165</th><th>Yes<br/>N = 37</th></tr></thead><tbody><tr><td>Antibiotics</td><td>159 (80.7)</td><td>84 (75.7)</td><td>73 (88.0)</td><td>0.04</td><td>124 (77.5)</td><td>31 (96.9)</td><td>0.01</td></tr><tr><td>Antiviral therapy</td><td>30 (15.1)</td><td>13 (11.4)</td><td>16 (19.5)</td><td>0.15</td><td>19 (11.7)</td><td>9 (27.3)</td><td>0.03</td></tr><tr><td>Systemic glucocorticoids</td><td>53 (27.0)</td><td>34 (29.5)</td><td>19 (22.6)</td><td>0.26</td><td>37 (23.3)</td><td>14 (42.4)</td><td>0.03</td></tr><tr><td>Admission to the ICU</td><td>60 (28.8)</td><td>31 (27.0)</td><td>27 (32.1)</td><td>0.44</td><td>33 (20.0)</td><td>26 (70.3)</td><td>&lt;0.01</td></tr><tr><td>Non-invasive ventilation</td><td>27 (12.9)</td><td>18 (15.7)</td><td>9 (10.7)</td><td>0.03</td><td>16 (9.7)</td><td>11 (29.7)</td><td>&lt;0.01</td></tr><tr><td>Invasive mechanical ventilation</td><td>23 (11.1)</td><td>14 (12.2)</td><td>8 (9.5)</td><td>0.65</td><td>-</td><td>23 (62.2)</td><td>&lt;0.01</td></tr><tr><td>ARDS</td><td>14 (6.7)</td><td>5 (4.3)</td><td>9 (10.7)</td><td>0.49</td><td>3 (1.8)</td><td>11 (29.7)</td><td>&lt;0.01</td></tr><tr><td>Length of hospital stay (days)</td><td>9 [6–14]</td><td>11 [7–17]</td><td>8 [5–10]</td><td>0.03</td><td>9 [6–13]</td><td>29 [19–34]</td><td>&lt;0.01</td></tr><tr><td>Death</td><td>17 (8.3)</td><td>7 (6.1)</td><td>10 (12.0)</td><td>0.20</td><td>-</td><td>17 (45.9)</td><td>NA</td></tr></tbody></table>

Data are presented as median [first through third quartiles] or number (%). Patients were classified according to the clinical diagnosis, which was available in 199 patients. Non-pneumonia diagnosis included bronchitis, acute exacerbation of COPD, exacerbation of interstitial lung disease, pulmonary edema, and other diagnosis. The composite criterion of “complicated course”, defined by death in hospital or at D60 or the need for invasive mechanical ventilation, was available for 202 patients.

Abbreviations: ARDS, Acute Respiratory Distress Syndrome; ICU, Intensive Care Unit.

occurred in ten (12 %) pneumonia patients, as compared to seven (6 %) non-pneumonia patients (p = 0.19). Interestingly, a complicated course was more frequently observed in pneumonia patients with bacterial coinfection (8/24, 33 %) as compared to those without bacterial coinfection (5/60, 8 %) (p = 0.02).

## 4. Discussion

This study investigated the clinical spectrum and outcomes of hMPV-associated lower respiratory tract infection in hospitalized adults. Patients were mostly elderly people with comorbid conditions, with a clinical diagnosis of pneumonia or acute bronchitis in two third of them and a bacterial coinfection documented in 29 % of patients. Among patients without coinfection (“pure” hMPV infection), the clinical diagnosis was pneumonia in 42 % of cases. In the 52 patients who had a chest-CT, the most frequent abnormality was ground glass opacity (41 %). A complicated course, defined as the death during hospital stay and/or the need for invasive mechanical ventilation, was observed in 18 % of patients, but up to 33 % of pneumonia patients with a bacterial coinfection.

In this cohort, we observed a high frequency of dyspnea and cough, in line with previous findings in hMPV-infected inpatients (Table 5) [2,3,6,11]. These symptoms are not specific of hMPV, since similar observations have been reported with other respiratory viruses [12]. Our population displayed a high rate of comorbid conditions and an advanced age. These demographical features, which have also been pointed out in RSV infection, differ from influenza-infected inpatients [2,3,6,11,13–18]. Paraclinical data revealed ground glass opacities and micronodules as predominant CT-scan abnormalities, in line with a previous report in hematological

<table><caption>**Table 5**
Overview of studies reporting cohorts of adult inpatients affected of hMPV-associated lower respiratory tract infections.</caption><thead><tr><th></th><th>Hamlin et al.<br/>2005<br/>Clin Infect Dis</th><th>Walsh et al.<sup>a</sup><br/>2008<br/>Arch Intern Med</th><th>Hasvold et al.<br/>2016<br/>J Crit Care</th><th>Loubet et al.<br/>2020<br/>Clin Microbiol Infect</th><th>Our cohort</th></tr></thead><tbody><tr><td>Design</td><td>Prospective</td><td>Prospective</td><td>Retrospective</td><td>Retrospective</td><td>Prospective</td></tr><tr><td>Patients</td><td>6</td><td>91</td><td>128</td><td>90</td><td>208</td></tr><tr><td>Median age</td><td>64</td><td>NA</td><td>55</td><td>78</td><td>74</td></tr><tr><td>Comorbidities</td><td>6 (100 %)</td><td>NA</td><td>89 (70 %)</td><td>73 (81 %)</td><td>187 (90 %)</td></tr><tr><td>Chronic immunosuppression</td><td>NA</td><td>NA</td><td>NA</td><td>15 (17 %)</td><td>67 (32 %)</td></tr><tr><td>Most common symptom</td><td>Cough (100 %)</td><td>Dyspnea (98 %)</td><td>NA</td><td>Fever (88 %)</td><td>Dyspnea (86 %)</td></tr><tr><td>Second most common symptom</td><td>Dyspnea (83 %)</td><td>Cough (94 %)</td><td>NA</td><td>Dyspnea (84 %)</td><td>Cough (85 %)</td></tr><tr><td>Most common lung CT-scan abnormality</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>GGO (41 %)<sup>b</sup></td></tr><tr><td>Virus-virus co-infection</td><td>1 (17 %)</td><td>NA</td><td>1 (1 %)</td><td>NA</td><td>26 (13 %)</td></tr><tr><td>Virus-bacterial co-infection</td><td>1 (17 %)</td><td>1 (2 %)<sup>c</sup></td><td>NA</td><td>NA</td><td>61 (29 %)</td></tr><tr><td>Final diagnosis of pneumonia</td><td>70 %</td><td>25 %</td><td>NA</td><td>36 %</td><td>42 %</td></tr><tr><td>Admission in ICU</td><td>NA</td><td>12 (13 %)</td><td>40 (31 %)</td><td>15 (17 %)</td><td>60 (29 %)</td></tr><tr><td>Invasive mechanical ventilation</td><td>0</td><td>11 (11 %)</td><td>22 (17 %)</td><td>NA</td><td>23 (11 %)</td></tr><tr><td>Hospital stay duration, days</td><td>10</td><td>9</td><td>5</td><td>7</td><td>9</td></tr><tr><td>Death</td><td>0</td><td>6 (7 %)</td><td>10 (8 %)</td><td>4 (4 %)</td><td>17 (8 %)</td></tr></tbody></table>

Data are presented as median [first through third quartiles] or number (%) unless otherwise stated.

<footnote>a Only the cohort of hospitalized patients.</footnote>

<footnote>b Among the 52 patients who had a lung CT-scan.</footnote>

<footnote>c Among the 31 patients who had a bacteriological examination of a respiratory sample.</footnote>
patients [19].

A bacterial documentation was obtained in 29 % of cases, a rate slightly higher than previously reported in hMPV-infected hospitalized adults but in the range of values, from 18 to 31 %, reported in RSV infection [2,3,6,11]. The predominant bacterial documentation was mixed respiratory flora, in line with recent findings showing this polymicrobial documentation as predominant in community-acquired pneumonia (CAP) inpatients with viral-bacterial coinfection [20]. Additionally, we observed that gram-negative bacilli (GNB), including Enterobacteriaceae and P. aeruginosa, accounted for 7 % of bacterial documentation in the whole cohort and 8 % in the subgroup of patients with a clinical diagnosis of pneumonia. These rates were slightly higher than those reported in cohorts of hospitalized patients with influenza infection, but in line with recent findings by Coussement et al. who reported a rate of GNB-related coinfection of 8 % in 309 patients with severe RSV infection [21–23]. This observation may be related to the advanced age of our population. Indeed, GNB have been shown predominant in cohorts of older patients with community-acquired pneumonia, probably linked to an age-dependent increased risk of aspiration [24–26].

Viral-bacterial coinfection has been shown to be associated with poor outcome in hospitalized adults with moderate-to-severe CAP [27–29]. In line with these results, we observed in the subpopulation of pneumonia patients a more complicated course in patients with a bacterial coinfection as compared to those without. This finding is original since none of the previous studies in hMPV-infected patients addressed this specific point, while at least one study reported similar results in RSV infection [18]. Admission to the ICU and hospital death occurred in 29 % and 8 % of our patients, respectively. Both these values were in the upper range (Table 5) of values reported in previous cohorts of hMPV-infected patients [2,3,6,11].

Multivariable analysis identified tachycardia and alteration of consciousness as independently associated with a complicated course. Interestingly, none of these parameters was related to respiratory failure. These findings should encourage clinicians to carefully take extrapulmonary clinical manifestations into account when caring for adult patients with lower respiratory tract infection. Indeed, the high burden of non-pulmonary signs and symptoms has been described for a long time in elderly and immunocompromised patients with either CAP or respiratory virus-associated infection [30,31]. Finally, these predictors of poor outcome may be helpful for clinicians in order to identify at-risk patients and guide the use of forthcoming drugs targeting hMPV.

Our study has several limitations. First, we did not control the diagnosis of hMPV infection. The decision to perform a respiratory mPCR was at the discretion of physicians, based on their clinical suspicion of lower respiratory tract infection; this might suggest a confounding of indication. However, recent results by our group have shown that mPCR tests were widely used by clinicians worldwide in a syndromic approach to the microbiological diagnosis in hospitalized patients [32]. Second, we did not control paraclinical investigations. A lung CT-scan was performed in only a quarter of patients, preventing any detailed analysis of CT-scan patterns in the whole study population. Some microbiological tests were only occasionally performed because the bacteriological work-up was at the attending clinician's discretion. It meant that some bacterial coinfections could have been missed, so the proportion of patients with coinfection could have been underestimated. Additionally, we did not collect post-infection clinical data such as pulmonary function test, which would have highlighted the long-term consequences of hMPV infection in survivors. Third, mPCR test differed from one center to another, but all the centers used tests with CE marking certification that guarantee high safety and level of performance. Fourth, we considered that any hMPV documentation within airways affirmed the diagnosis of hMPV infection, regardless of the site of sampling (upper or lower respiratory tract). This assumption was supported by the natural history of Pneumoviridae-related infections, which are known to invade the whole respiratory tract [33]. Fifth, we chose a primary composite end point. Indeed, considering the predictable low hospital mortality, we did not choose hospital death as primary end point, because the low frequency of the event would have favored the absence of difference between groups.

In conclusion, hMPV-associated lower respiratory tract infections in adult inpatients mostly involved elderly people with pre-existing conditions. The most frequent clinical diagnosis was pneumonia. A bacterial coinfection was documented in 29 % of patients. The need for mechanical ventilation and/or the death were observed in 18 % of patients, but up to a third of pneumonia patients with a bacterial coinfection. Our data highlight the crucial need for development of antiviral drugs targeting hMPV.

## Ethics to approval and consent to participate

This study was approved by the institutional review board of the French Society of Respiratory Diseases (Reference CEPRO 2017-037) according to the French regulations. The board waived the need for signing consent for patients included in the study.

## Consent for publication

Not applicable.

## Availability of supporting data

Data and materials supporting the findings of this study can be entirely shared if asking.

## Funding

None.
## Data availability statement

The data needed to evaluate the conclusions in the paper are present in the paper or the ESM. Raw data are available upon request from the corresponding authors under a material/data transfer agreement.

## CRediT authorship contribution statement

**Quentin Philippot:** Writing – review & editing, Writing – original draft, Investigation, Conceptualization. **Blandine Rammaert:** Investigation. **Gaëlle Dauriat:** Investigation. **Cédric Daubin:** Investigation. **Frédéric Schlemmer:** Investigation. **Adrien Costantini:** Investigation. **Yacine Tandjaoui-Lambiotte:** Investigation. **Mathilde Neuville:** Investigation. **Emmanuelle Desrochettes:** Investigation. **Alexis Ferré:** Investigation. **Laetitia Bodet Contentin:** Investigation. **François-Xavier Lescure:** Investigation. **Bruno Megarbane:** Investigation. **Antoine Belle:** Investigation. **Jean Dellamonica:** Investigation. **Sylvain Jaffuel:** Investigation. **Jean-Luc Meynard:** Investigation. **Jonathan Messika:** Investigation. **Nicolas Lau:** Investigation. **Nicolas Terzi:** Investigation. **Isabelle Runge:** Investigation. **Olivier Sanchez:** Investigation. **Benjamin Zuber:** Investigation. **Emmanuel Guerot:** Investigation. **Anahita Rouze:** Investigation. **Patricia Pavese:** Investigation. **François Bénézit:** Investigation. **Jean-Pierre Quenot:** Investigation. **Xavier Souloy:** Investigation. **Anne Lyse Fanton:** Investigation. **David Boutoille:** Investigation. **Vincent Bunel:** Investigation. **Astrid Vabret:** Investigation. **Jacques Gaillat:** Investigation. **Anne Bergeron:** Supervision, Conceptualization. **Nathanaël Lapidus:** Formal analysis. **Muriel Fartoukh:** Investigation. **Guillaume Voiriot:** Writing – review & editing, Writing – original draft, Investigation, Funding acquisition.

## Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Astrid VABRET disclosed payment or honoraria for lectures, presentations and support for attending meetings and/or travel from ANOFI, ASTRA ZENECA, MODERNA, and participation on a Data Safety Monitoring Board from SANOFI, MSD, MODERNA and GSK. Frederic Schlemmer disclosed consulting fees from Pfizer, payment or honoraria for lectures, presentations from Gilead, and participation on a Data Safety Monitoring Board from Boerhinger Ingelheim, Chiesi, Elivie, Gilead, GlaxoSmithKline and Oxyvie. Anne Bergeron disclosed payment or honoraria for lectures, presentations and support for attending meetings and/or travel from Astra Zeneca and Novartis, and participation on a Data Safety Monitoring Board from Enanta. Anahita Rouzé disclosed payment or honoraria for lectures, presentations and support for attending meetings and/or travel from MSD, Gilead, Mundipharma. Blandine RAMMAERT disclosed payment or honoraria for lectures, presentations from Gilead. Cedric Daubin disclosed support for attending meetings and/or travel from Gilead. Nicolas Terzi disclosed payment or honoraria for lectures, presentations from Pfizer and Boehringer Ingelheim, and support for attending meetings and/or travel from Gilead. Quentin Philippot disclosed payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and Elsevier, and grants or contracts from APHP, ARS Ile de France and Inserm Fondation Bettencourt Schueller, and support for the present manuscript from SOS Oxygen. Other authors did not disclose competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

This study has been supported by the European Research Network on Artificial Ventilation (REVA Network), the French Clinical Research Network on Infectious Diseases (RENARCI Network) and the French Research Network on Lung Infectious Diseases (GREPI Network).

## Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e33231.

## List of abbreviations

CAP community-acquired pneumonia

chest-CT chest computerized tomography

COPD chronic obstructive pulmonary disease

ESM electronic supplementary material

GNB gram-negative bacilli

hMPV Human metapneumovirus

ICU intensive care unit

mPCR multiplex polymerase chain reaction

RSV respiratory syncytial virus
References

[1] S. Jain, W.H. Self, R.G. Wunderink, S. Fakhran, R. Balk, A.M. Bramley, C. Reed, C.G. Grijalva, E.J. Anderson, D.M. Courtney, J.D. Chappell, C. Qi, E.M. Hart, F. Carroll, C. Trabue, H.K. Donnelly, D.J. Williams, Y. Zhu, S.R. Arnold, K. Ampofo, G.W. Waterer, M. Levine, S. Lindstrom, J.M. Winchell, J.M. Katz, D. Erdman, E. Schneider, L.A. Hicks, J.A. McCullers, A.T. Pavia, K.M. Edwards, L. Finelli, CDC EPIC study team, community-acquired pneumonia requiring hospitalization among U.S. Adults, N. Engl. J. Med. 373 (2015) 415-427, https://doi.org/10.1056/NEJMoa1500245.

[2] E.E. Walsh, D.R. Peterson, A.R. Falsey, Human metapneumovirus infections in adults: another piece of the puzzle, Arch. Intern. Med. 168 (2008) 2489-2496, https://doi.org/10.1001/archinte.168.22.2489.

[3] P. Loubet, P. Mathieu, N. Lenzi, F. Galtier, F. Lainé, Z. Lesieur, P. Vanhems, X. Duval, D. Postil, S. Amour, S. Rogez, G. Lagathu, A.-S. L'Honneur, V. Foulongne, N. Houhou, B. Lina, F. Carrat, O. Launay, Fluvac study group, Characteristics of human metapneumovirus infection in adults hospitalized for community-acquired influenza-like illness in France, 2012-2018: a retrospective observational study, Clin. Microbiol. Infect. 27 (2021) e1-127.e6, https://doi.org/10.1016/j.cmi.2021.04.005.

[4] B.G. van den Hoogen, J.C. de Jong, J. Groen, T. Kuiken, R. de Groot, R.A. Fouchier, A.D. Osterhaus, A newly discovered human pneumovirus isolated from young children with respiratory tract disease, Nat. Med. 7 (2001) 719-724, https://doi.org/10.1038/89098.

[5] J.S.M. Peiris, W.-H. Tang, K.-H. Chan, P.-L. Khong, Y. Guan, Y.-L. Lau, S.S. Chiu, Children with respiratory disease associated with metapneumovirus in Hong Kong, Emerg. Infect. Dis. 9 (2003) 628-633, https://doi.org/10.3201/eid0906.030009.

[6] J. Hasvold, M. Sjoding, K. Pohl, C. Cooke, R.C. Hyzy, The role of human metapneumovirus in the critically ill adult patient, J. Crit. Care 31 (2016) 233-237, https://doi.org/10.1016/j.jcrc.2015.09.035.

[7] P.I. Andersen, K. Krpina, A. Ianevski, N. Shtaida, E. Jo, J. Yang, S. Koit, T. Tenson, V. Hukkanen, M.W. Anthonsen, M. Bjoras, M. Evander, M.P. Windisch, E. Zusinaite, D.E. Kainov, Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine, Viruses 11 (2019) E964, https://doi.org/10.3390/v11100964.

[8] D. Jochmans, S. van Nieuwkoop, S.L. Smits, J. Neyts, R.A.M. Fouchier, B.G. van den Hoogen, Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters, Antimicrob. Agents Chemother. 60 (2016) 4620-4629, https://doi.org/10.1128/AAC.00709-16.

[9] J. Huang, P. Chopra, L. Liu, T. Nagy, J. Murray, R.A. Tripp, G.-J. Boons, J.J. Mousa, Structure, immunogenicity, and conformation-dependent receptor binding of the postfusion human metapneumovirus F Protein, J. Virol. 95 (2021) e0059321, https://doi.org/10.1128/JVI.00593-21.

[10] P. Kumar, M. Srivastava, Prophylactic and therapeutic approaches for human metapneumovirus, Virus disease 29 (2018) 434-444, https://doi.org/10.1007/s13337-018-0498-5.

[11] M.E. Hamelin, S. Côté, J. Laforge, N. Lampron, J. Bourbeau, K. Weiss, R. Gilca, G. DeSerres, G. Boivin, Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease, Clin. Infect. Dis. 41 (2005) 498-502, https://doi.org/10.1086/431981.

[12] L.C. Jennings, T.P. Anderson, K.A. Beynon, A. Chua, R.T.R. Laing, A.M. Werno, S.A. Young, S.T. Chambers, D.R. Murdoch, Incidence and characteristics of viral community-acquired pneumonia in adults, Thorax 63 (2008) 42-48, https://doi.org/10.1136/thx.2006.075077.

[13] B. Ackerson, H.F. Tseng, L.S. Sy, Z. Solano, J. Slezak, Y. Luo, C.A. Fischetti, V. Shinde, Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults, Clin. Infect. Dis. 69 (2019) 197-203, https://doi.org/10.1093/cid/ciy991.

[14] B.A. Leaver, B.J. Smith, L. Irving, D.F. Johnson, S.Y.C. Tong, Hospitalisation, morbidity and outcomes associated with respiratory syncytial virus compared with influenza in adults of all ages, Influenza Other Respir Viruses 16 (2022) 474-480, https://doi.org/10.1111/irv.12909.

[15] C. Volling, K. Hassan, T. Mazzulli, K. Green, A. Al-Den, P. Hunter, R. Mangat, J. Ng, A. McGeer, Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study, BMC Infect. Dis. 14 (2014) 665, https://doi.org/10.1186/s12879-014-0665-2.

[16] K. Widmer, Y. Zhu, J.V. Williams, M.R. Griffin, K.M. Edwards, H.K. Talbot, Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults, J. Infect. Dis. 206 (2012) 56-62, https://doi.org/10.1093/infdis/jis309.

[17] N. Lee, G.C.Y. Lui, K.T. Wong, T.C.M. Li, E.C.M. Tse, J.Y.C. Chan, J. Yu, S.S.M. Wong, K.W. Choi, R.Y.K. Wong, L.K.L. Ngai, D.S.C. Hui, P.K.S. Chan, High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections, Clin. Infect. Dis. 57 (2013) 1069-1077, https://doi.org/10.1093/cid/cit471.

[18] Y. Zhang, Y. Wang, J. Zhao, Z. Xiong, Y. Fan, W. Zhang, X. Zou, C. Wang, J. Han, B. Li, B. Lu, B. Cao, CAP-China Network, Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China, Influenza Other Respir Viruses 14 (2020) 483-490, https://doi.org/10.1111/irv.12754.

[19] C. Godet, J. Le Goff, A. Beby-Defaux, M. Robin, E. Raffoux, B. Arnulf, F. Roblot, J.P. Frat, N. Maillard, A. Tazi, A. Bergeron, Human metapneumovirus pneumonia in patients with hematological malignancies, J. Clin. Virol. 61 (2014) 593-596, https://doi.org/10.1016/j.jcv.2014.08.019.

[20] D.M. Musher, S.S. Jesudasan, J.W. Barwatt, D.N. Cohen, B.J. Moss, M.C. Rodríguez-Barradas, Normal respiratory flora as a cause of community-acquired pneumonia, Open Forum Infect. Dis. 7 (2020) ofa307, https://doi.org/10.1093/ofid/ofa307.

[21] C.C. Blyth, S.A.R. Webb, J. Kok, D.E. Dwyer, S.J. van Hal, H. Foo, A.N. Ginn, A.M. Kesson, I. Seppelt, J.R. Iredell, ANZIC Influenza Investigators, COSI Microbiological Investigators, the impact of bacterial and viral co-infection in severe influenza, Influenza Other Respir Viruses 7 (2013) 168-176, https://doi.org/10.1111/j.1750-2659.2012.00360.x.

[22] C. Cillóniz, S. Ewig, R. Menéndez, M. Ferrer, E. Polverino, S. Reyes, A. Gabarrús, M.A. Marcos, J. Cordoba, J. Mensa, A. Torres, Bacterial co-infection with H1N1 infection in patients with community acquired pneumonia, J. Infect. 65 (2012) 223-230, https://doi.org/10.1016/j.jinf.2012.04.009.

[23] J. Coussement, B. Zuber, E. Garrigues, A. Gros, C. Vanduweren, N. Epaillard, G. Voiriot, Y. Tandjaoui-Lambiotte, J.-B. Lascarrou, F. Boissier, V. Lemiale, D. Contou, S. Hraiech, A.-P. Meert, B. Sauneuf, A. Munting, S. Ricome, J. Messika, G. Muller, H. Njimi, D. Grimaldi, Characteristics and outcomes of patients in the ICU with respiratory syncytial virus compared with those with influenza infection: a multicenter matched cohort study, S0012-3692, Chest (22) (2022), https://doi.org/10.1016/j.chest.2021.12.670, 00057-5.

[24] A.A. El-Solh, A.T. Aquilina, R.S. Dhillon, F. Ramadan, P. Nowak, J. Davies, Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia, Am. J. Respir. Crit. Care Med. 166 (2002) 1038-1043, https://doi.org/10.1164/rccm.200202-1230C.

[25] X. Han, X. Liu, L. Chen, Y. Wang, H. Li, F. Zhou, X. Xing, C. Zhang, L. Suo, J. Wang, G. Yu, G. Wang, X. Yao, H. Yu, L. Wang, M. Liu, C. Xue, B. Liu, X. Zhu, Y. Li, Y. Xiao, X. Cui, L. Li, B. Cao, CAP-China network, Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients, BMC Infect. Dis. 20 (2020) 668, https://doi.org/10.1186/s12879-020-05362-3.

[26] X. Han, F. Zhou, H. Li, X. Xing, L. Chen, Y. Wang, C. Zhang, X. Liu, L. Suo, J. Wang, G. Yu, G. Wang, X. Yao, H. Yu, L. Wang, M. Liu, C. Xue, B. Liu, X. Zhu, Y. Li, Y. Xiao, X. Cui, L. Li, J.E. Purdy, B. Cao, CAP-China network, Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia, BMC Infect. Dis. 18 (2018) 192, https://doi.org/10.1186/s12879-018-3098-5.

[27] G. Voiriot, B. Visseaux, J. Cohen, L.B.L. Nguyen, M. Neuville, C. Morbieu, C. Burdet, A. Radjou, F.-X. Lescure, R. Smonig, L. Armand-Lefevre, B. Mourvillier, Y. Yazdanpanah, J.-F. Soubiou, R. Ruckly, N. Houhou-Fidouh, J.-F. Timsit, Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia, Crit. Care 20 (2016) 375, https://doi.org/10.1186/s13054-016-1517-9.

[28] B. Montull, R. Menéndez, A. Torres, S. Reyes, R. Méndez, R. Zalacafín, A. Capelastegui, O. Rajas, L. Borderías, J. Martin-Villasclaras, S. Bello, I. Alfageme, F. Rodríguez de Castro, J. Rello, L. Molinos, J. Ruiz-Manzano, NAC calidad group, predictors of severe sepsis among patients hospitalized for community-acquired pneumonia, PLoS One 11 (2016) e0145929, https://doi.org/10.1371/journal.pone.0145929.

[29] Y. Liu, L. Ling, S.H. Wong, M.H. Wang, J.R. Fitzgerald, X. Zou, S. Fang, X. Liu, X. Wang, W. Hu, H. Chan, Y. Wang, D. Huang, Q. Li, W.T. Wong, G. Choi, H. Zou, D.S. Hui, J. Yu, G. Tse, T. Gin, W.K. Wu, M.T. Chan, L. Zhang, Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients, E ClinicalMedicine 37 (2021) 100955, https://doi.org/10.1016/j.eclinm.2021.100955.

[30] N. Fernández-Sabé, J. Carratalà, B. Rosón, J. Dorca, R. Verdager, F. Manresa, F. Gudiol, Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes, Medicine (Baltim.) 82 (2003) 159-169, https://doi.org/10.1097/01.md.0000076005.64510.87.
[31] T.J. Marrie, E.V. Haldane, R.S. Faulkner, H. Durant, C. Kwan, Community-acquired pneumonia requiring hospitalization. Is it different in the elderly? J. Am. Geriatr. Soc. 33 (1985) 671-680, https://doi.org/10.1111/j.1532-5415.1985.tb01775.x.

[32] Q. Philippot, V. Labbé, J. Pichon, M. Djibré, M. Fartoukh, G. Voiriot, Diagnosis and management of respiratory viruses in critically ill adult patients: an international survey of knowledge and practice among intensivists, Ann. Intensive Care 10 (2020) 50, https://doi.org/10.1186/s13613-020-00660-0.

[33] M.-A. Rameix-Welti, R. Le Goffic, P.-L. Hervé, J. Sourimant, A. Rémot, S. Riffault, Q. Yu, M. Galloux, E. Gault, J.-F. Eléouët, Visualizing the replication of respiratory syncytial virus in cells and in living mice, Nat. Commun. 5 (2014) 5104, https://doi.org/10.1038/ncomms6104.